vs
Progyny, Inc.（PGNY）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Progyny, Inc.的季度营收约是Sotera Health Co的1.0倍（$318.4M vs $303.4M）。Sotera Health Co净利率更高（11.5% vs 3.9%，领先7.6%）。Progyny, Inc.同比增速更快（6.7% vs 4.6%）。Sotera Health Co自由现金流更多（$52.4M vs $48.6M）。过去两年Sotera Health Co的营收复合增速更高（10.6% vs 7.0%）
Progyny, Inc.是总部位于美国的领先生育与家庭构建福利服务商，主要与企业雇主合作，提供试管婴儿、生育力保存、收养协助、代孕支持等综合生育相关福利方案，覆盖多个行业的雇员群体。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
PGNY vs SHC — 直观对比
营收规模更大
PGNY
是对方的1.0倍
$303.4M
营收增速更快
PGNY
高出2.1%
4.6%
净利率更高
SHC
高出7.6%
3.9%
自由现金流更多
SHC
多$3.8M
$48.6M
两年增速更快
SHC
近两年复合增速
7.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $318.4M | $303.4M |
| 净利润 | $12.5M | $34.8M |
| 毛利率 | 24.1% | 54.7% |
| 营业利润率 | 4.8% | 23.2% |
| 净利率 | 3.9% | 11.5% |
| 营收同比 | 6.7% | 4.6% |
| 净利润同比 | 18.5% | 182.8% |
| 每股收益（稀释后） | $0.14 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PGNYSHC
| Q4 25 | $318.4M | $303.4M | ||
| Q3 25 | $313.3M | $311.3M | ||
| Q2 25 | $332.9M | $294.3M | ||
| Q1 25 | $324.0M | $254.5M | ||
| Q4 24 | $298.4M | $290.2M | ||
| Q3 24 | $286.6M | $285.5M | ||
| Q2 24 | $304.1M | $276.6M | ||
| Q1 24 | $278.1M | $248.2M |
净利润PGNYSHC
| Q4 25 | $12.5M | $34.8M | ||
| Q3 25 | $13.9M | $48.4M | ||
| Q2 25 | $17.1M | $8.0M | ||
| Q1 25 | $15.1M | $-13.3M | ||
| Q4 24 | $10.5M | $12.3M | ||
| Q3 24 | $10.4M | $17.0M | ||
| Q2 24 | $16.5M | $8.8M | ||
| Q1 24 | $16.9M | $6.3M |
毛利率PGNYSHC
| Q4 25 | 24.1% | 54.7% | ||
| Q3 25 | 23.2% | 57.0% | ||
| Q2 25 | 23.7% | 56.6% | ||
| Q1 25 | 23.4% | 53.2% | ||
| Q4 24 | 21.3% | 56.6% | ||
| Q3 24 | 20.7% | 55.4% | ||
| Q2 24 | 22.5% | 55.2% | ||
| Q1 24 | 22.4% | 51.2% |
营业利润率PGNYSHC
| Q4 25 | 4.8% | 23.2% | ||
| Q3 25 | 6.9% | 23.4% | ||
| Q2 25 | 7.3% | 6.4% | ||
| Q1 25 | 7.5% | -5.8% | ||
| Q4 24 | 5.3% | 30.0% | ||
| Q3 24 | 4.3% | 28.2% | ||
| Q2 24 | 6.8% | 27.8% | ||
| Q1 24 | 6.7% | 21.4% |
净利率PGNYSHC
| Q4 25 | 3.9% | 11.5% | ||
| Q3 25 | 4.4% | 15.5% | ||
| Q2 25 | 5.1% | 2.7% | ||
| Q1 25 | 4.6% | -5.2% | ||
| Q4 24 | 3.5% | 4.2% | ||
| Q3 24 | 3.6% | 6.0% | ||
| Q2 24 | 5.4% | 3.2% | ||
| Q1 24 | 6.1% | 2.5% |
每股收益（稀释后）PGNYSHC
| Q4 25 | $0.14 | $0.12 | ||
| Q3 25 | $0.15 | $0.17 | ||
| Q2 25 | $0.19 | $0.03 | ||
| Q1 25 | $0.17 | $-0.05 | ||
| Q4 24 | $0.12 | $0.05 | ||
| Q3 24 | $0.11 | $0.06 | ||
| Q2 24 | $0.17 | $0.03 | ||
| Q1 24 | $0.17 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.2M | $344.6M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $516.0M | $606.0M |
| 总资产 | $742.4M | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资PGNYSHC
| Q4 25 | $112.2M | $344.6M | ||
| Q3 25 | $134.0M | $299.2M | ||
| Q2 25 | $132.5M | $332.4M | ||
| Q1 25 | $109.2M | $304.4M | ||
| Q4 24 | $162.3M | $277.2M | ||
| Q3 24 | $91.5M | $306.7M | ||
| Q2 24 | $95.0M | $246.1M | ||
| Q1 24 | $115.0M | $261.1M |
总债务PGNYSHC
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益PGNYSHC
| Q4 25 | $516.0M | $606.0M | ||
| Q3 25 | $560.0M | $550.5M | ||
| Q2 25 | $515.0M | $511.3M | ||
| Q1 25 | $467.2M | $414.1M | ||
| Q4 24 | $422.1M | $404.9M | ||
| Q3 24 | $434.9M | $470.2M | ||
| Q2 24 | $456.2M | $422.8M | ||
| Q1 24 | $571.6M | $429.4M |
总资产PGNYSHC
| Q4 25 | $742.4M | $3.3B | ||
| Q3 25 | $795.2M | $3.2B | ||
| Q2 25 | $761.0M | $3.2B | ||
| Q1 25 | $730.3M | $3.1B | ||
| Q4 24 | $607.1M | $3.1B | ||
| Q3 24 | $660.0M | $3.1B | ||
| Q2 24 | $698.6M | $3.1B | ||
| Q1 24 | $794.3M | $3.1B |
负债/权益比PGNYSHC
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.2M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $48.6M | $52.4M |
| 自由现金流率自由现金流/营收 | 15.3% | 17.3% |
| 资本支出强度资本支出/营收 | 1.8% | 16.7% |
| 现金转化率经营现金流/净利润 | 4.34× | 2.96× |
| 过去12个月自由现金流最近4个季度 | $191.8M | $149.2M |
8季度趋势，按日历期对齐
经营现金流PGNYSHC
| Q4 25 | $54.2M | $103.1M | ||
| Q3 25 | $50.7M | $71.2M | ||
| Q2 25 | $55.5M | $57.4M | ||
| Q1 25 | $49.8M | $55.5M | ||
| Q4 24 | $52.2M | $55.7M | ||
| Q3 24 | $44.5M | $97.5M | ||
| Q2 24 | $56.7M | $61.3M | ||
| Q1 24 | $25.7M | $9.7M |
自由现金流PGNYSHC
| Q4 25 | $48.6M | $52.4M | ||
| Q3 25 | $46.0M | $35.0M | ||
| Q2 25 | $50.2M | $26.2M | ||
| Q1 25 | $47.0M | $35.6M | ||
| Q4 24 | $50.3M | $-10.2M | ||
| Q3 24 | $42.7M | $61.1M | ||
| Q2 24 | $55.8M | $19.4M | ||
| Q1 24 | $24.9M | $-25.2M |
自由现金流率PGNYSHC
| Q4 25 | 15.3% | 17.3% | ||
| Q3 25 | 14.7% | 11.2% | ||
| Q2 25 | 15.1% | 8.9% | ||
| Q1 25 | 14.5% | 14.0% | ||
| Q4 24 | 16.8% | -3.5% | ||
| Q3 24 | 14.9% | 21.4% | ||
| Q2 24 | 18.4% | 7.0% | ||
| Q1 24 | 8.9% | -10.2% |
资本支出强度PGNYSHC
| Q4 25 | 1.8% | 16.7% | ||
| Q3 25 | 1.5% | 11.6% | ||
| Q2 25 | 1.6% | 10.6% | ||
| Q1 25 | 0.9% | 7.8% | ||
| Q4 24 | 0.6% | 22.7% | ||
| Q3 24 | 0.6% | 12.7% | ||
| Q2 24 | 0.3% | 15.2% | ||
| Q1 24 | 0.3% | 14.1% |
现金转化率PGNYSHC
| Q4 25 | 4.34× | 2.96× | ||
| Q3 25 | 3.65× | 1.47× | ||
| Q2 25 | 3.24× | 7.21× | ||
| Q1 25 | 3.31× | — | ||
| Q4 24 | 4.95× | 4.52× | ||
| Q3 24 | 4.27× | 5.73× | ||
| Q2 24 | 3.44× | 7.00× | ||
| Q1 24 | 1.52× | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
